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Abstract
ADAMs (a disintegrin and metalloproteinases) comprise a new
gene family of metalloproteinases, and may play roles in cell-cell
interaction, cell migration, signal transduction, shedding of
membrane-anchored proteins and degradation of extracellular
matrix. We screened the mRNA expression of 10 different
ADAMs with a putative metalloproteinase motif in synovial
tissues from patients with rheumatoid arthritis (RA) or
osteoarthritis (OA). Reverse transcription PCR and real-time
quantitative PCR analyses indicated that among the ADAMs,
ADAM15 mRNA was more frequently expressed in the RA
samples and its expression level was significantly 3.8-fold higher
in RA than in OA (p < 0.01). In situ hybridization,
immunohistochemistry and immunoblotting demonstrated that
ADAM15 is expressed in active and precursor forms in the
synovial lining cells, endothelial cells of blood vessels and
macrophage-like cells in the sublining layer of RA synovium.
There was a direct correlation between ADAM15 mRNA
expression levels and vascular density in the synovial tissues (r
= 0.907, p < 0.001; n = 20). ADAM15 was constitutively
expressed in RA synovial fibroblasts and human umbilical vein
endothelial cells (HUVECs), and the expression level was
increased in HUVECs by treatment with vascular endothelial
growth factor (VEGF)165. On the other hand, ADAM15
expression in RA synovial fibroblasts was enhanced with
VEGF165  only if vascular endothelial growth factor receptor
(VEGFR)-2 expression was induced by treatment with tumor
necrosis factor-α , and the expression was blocked with
SU1498, a specific inhibitor of VEGFR-2. These data
demonstrate that ADAM15 is overexpressed in RA synovium
and its expression is up-regulated by the action of VEGF165
through VEGFR-2, and suggest the possibility that ADAM15 is
involved in angiogenesis in RA synovium.
Introduction
In rheumatoid arthritis (RA), the affected joints develop chronic
synovitis that is characterized by hyperplasia of lining cells,
infiltration of inflammatory cells and abundant neovasculariza-
tion. Various factors such as proteinases, growth factors and
cytokines are produced in the RA synovium and implicated in
the destruction of articular cartilage and subchondral bones,
leading to disability of the joints. Among the proteinases,
matrix metalloproteinases (MMPs), a gene family of zinc metal-
loproteinases, are well known to play a major role in the prote-
olytic degradation of extracellular matrix (ECM)
macromolecules of cartilage and bone, which is a key step in
joint destruction in RA [1]. Members of a new family of metal-
loproteinases, the 'a disintegrin and metalloproteinases'
(ADAMs), which share structural homology with MMPs and
snake venom metalloproteinases, have recently been cloned.
ADAMs consist of propeptide, metalloproteinase, disintegrin-
like, cysteine-rich, epidermal growth factor-like,
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transmembrane and cytoplasmic tail domains [1,2]. Members
are classified into putative proteinase-type and non-protein-
ase-type ADAMs according to the different structures of the
catalytic site motif in the metalloproteinase domain [1,3].
Although the specific biological functions of ADAMs are not
well elucidated at the present time, they may be involved in
cell-cell interaction, cell migration, signal transduction, shed-
ding of various membrane-anchored proteins and degradation
of ECM components under pathophysiological conditions
such as fertilization [4,5], morphogenesis [6,7], angiogenesis
[8] and cancer [9]. The expression of ADAM10, ADAM15 and
ADAM17 in arthritic cartilage and synovial tissues has been
examined [10-12], but there are no reports of systematic anal-
yses of the expression of ADAMs in arthritic joint tissues. In
addition, little or no information is available for correlation
between the expression and synovial pathology or for regula-
tion mechanism of ADAM expression. Angiogenesis in the syn-
ovium during RA begins at the early stage of the disease and
is crucial for progression of the synovitis [13]. Vascular
endothelial growth factor (VEGF), which has five different iso-
forms (VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206)
is known to play a key role in the angiogenesis in RA synovium
[13,14]. All these VEGF isoforms bind to high-affinity recep-
tors, namely VEGFR-1 (fms-like tyrosine kinase; Flt-1) and
VEGFR-2 (kinase insert domain-containing receptor; KDR).
Neuropilin-1, an isoform-specific co-receptor of VEGFR-2,
enhances the bioactivity of VEGF165 by increasing its binding
affinity for VEGFR-2 [15]. Interestingly, binding of VEGF to its
receptors on endothelial cells enhances not only their prolifer-
ation and migration but also production of MMPs [16-18]. In
addition, VEGF stimulates other cells such as chondrocytes to
induce expression of MMPs [19]. Thus, it might be possible to
speculate that VEGF regulates the expression of proteinase-
type ADAMs.
In the present study, we examined the expression of 10 differ-
ent ADAM species with a putative metalloproteinase motif in
synovial tissues of RA and osteoarthritis (OA), correlation of
ADAM15 expression with synovial pathology, localization of
ADAM15 in RA synovium, and the mechanism of regulation of
ADAM15 expression in RA synovial fibroblasts and endothelial
cells. Our results demonstrate that ADAM15 is expressed in
lining cells, endothelial cells of blood vessels and macro-
phage-like cells in the sublining layer of RA synovium with a
direct correlation with vascular density in the synovium, and
that the expression of ADAM15 is up-regulated by the action
of VEGF165 via VEGFR-2.
Materials and methods
Clinical samples and histology
Synovial tissues were obtained from patients with RA (56 ± 14
years old (mean ± SD); n = 16) or OA (73 ± 6 years old; n =
20) at total knee arthroplasty. Diagnosis of the patients with
RA or OA was based on the 1987 revised American Rheuma-
tism Association Criteria for RA [20] and the American Rheu-
matism Association Criteria for OA [21]. Synovial specimens
were fixed with periodate-lysine-paraformaldehyde, and paraf-
fin sections stained with hematoxylin and eosin were analyzed
by light microscopy according to our grading system of syno-
vial lining cell hyperplasia, cellular infiltration and fibrosis [22].
For the experimental use of the surgical specimens, written
informed consent was obtained from the patients according to
the hospital ethical guidelines.
Reverse transcription-PCR
Total RNA was extracted directly from RA (n = 16) and OA (n
= 20) synovial tissues and evaluated by using the Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA)
as descried previously [9]. By using a random hexamer of oli-
gonucleotides (Takara Bio Inc., Otsu, Japan), cDNAs were
prepared from total RNA with SuperScript II reverse tran-
scriptase (Life Technologies Inc., Rockville, MD, USA). The
reaction product was subjected to reverse transcription (RT)-
PCR analysis on the expression of ADAMs 8, 9, 10, 12, 15,
17, 20, 21, 28 and 30, VEGFR-1, VEGFR-2, neuropilin-1 and
β -actin for 25–30 cycles. PCR was carried out in 50 µl reac-
tion volume containing 800 nM of each primer, 220 µM of
dNTPs and 1 unit of ExTaq DNA polymerase (Takara Bio Inc.).
The thermal cycle was 1 minute at 94°C, 1 minute at 62°C for
ADAMs 8, 9, 10, 12, 17, 20, 21, 28 and 30, 67°C for
ADAM15, 64°C for VEGFR-1, 63°C for VEGFR-2 and
neuropilin-1 and 65°C for β -actin, and 1 minute at 72°C, fol-
lowed by 3 minutes at 72°C for the final extension. The nucle-
otide sequences of the PCR primers and the expected sizes
of the amplified cDNA fragments are shown in Table 1. Aliq-
uots of the PCR products were electrophoresed in 2% agar-
ose gels, and stained with ethidium bromide. For positive
controls, total RNA was extracted from cancer cell lines as
described previously [9]. The specific amplification of these
ADAMs, VEGFRs, neuropilin-1 and β -actin was confirmed by
direct sequencing of the PCR products.
Real-time quantitative PCR for ADAM15
The mRNA expression levels of ADAM15 were evaluated in a
TaqMan real-time PCR assay using the ABI Prism 7000
sequence detection system (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer's protocols. Cycling
conditions were 50°C for 2 minutes, 95°C for 10 minutes, and
then 40 cycles at 95°C for 15 seconds and 60°C for 1 minute.
Primers were designed and selected using Primer Express
software (Applied Biosystems). Sequences of the primers and
TaqMan probe for ADAM15 were as follows: forward primer,
5'-GGCAATCGAGGCAGCAAAT-3'; reverse primer, 5'-
TGGTGGAGATCAGCCCAAAC-3'; and TaqMan probe, 5'-
FAM-CAGCTGTCACCCTCGAAAACTTCCTCC-TAMRA-3'.
The relative quantification value of ADAM15 was normalized to
an endogenous control, 18S ribosomal RNA, after confirming
that ADAM15 and ribosomal 18S cDNAs were amplified with
the same efficiency according to the manufacturer's protocol.
The total gene specificity of the nucleotide sequences chosenAvailable online http://arthritis-research.com/content/7/6/R1158
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for the primers and probe and the absence of DNA polymor-
phisms were ascertained using BLASTN and Entrez from the
National Center for Biotechnology Information web site [23].
In situ hybridization
Paraffin sections of the RA synovial tissues (n = 5) were used
for  in situ hybridization of ADAM15 according to a
modification of our methods used previously [19]. Briefly, the
sections were treated with proteinase K (5 µg/ml; Sigma-
Aldrich Inc., St Louis, MO, USA) in 10 mM Tris-HCl buffer, pH
8.0, and 1 mM ethylenediaminetetraacetic acid, and endog-
enous peroxidase was blocked with 0.3% hydrogen peroxide
in methanol. Single-stranded sense and anti-sense digoxi-
genin-labeled RNA probes were generated by in vitro tran-
Table 1
Sequences of the primers used for RT-PCR
Primer's name Product Oligonucleotide sequence Size (base pairs) Accession number
ADAM8 Forward 5'-GCCGTCTTCAGGCCTCGGCCCGGGGACTCT-3' 651 NM001109
Reverse 5'-AGGGGCGTTGGCGAGGCACACCGACTGCGG-3'
ADAM9 Forward 5'-GCTGTCTTGCCACAGACCCGGTATGTGGAG-3' 604 HSU41766
Reverse 5'-TGGAATATTAAGAAGGCAGTTTCCTCCTTT-3'
ADAM10 Forward 5'-ATCCAGTCATGTTAAAGCGATTGATACAATTTAC-3' 434 NM001110
Reverse 5'-TCCAAAGTTATGTCCAACTTCGTGAGCAAAAGTAA-3'
ADAM12 Forward 5'-GAGACCCTCAAGGCAACTAAGTATGTGGAG-3' 627 AF023476
Reverse 5'-CGGCAGGTTAAACAGGCACACCCCCATTCC-3'
ADAM15 Forward 5'-CTGGGACAGCGCCACATTCGCCGGAGGCGG-3' 688 HSU41767
Reverse 5'-TCCGCAGAAAGCAGCCATAGGGGGTAGGCT-3'
ADAM17 Forward 5'-AGAGCTGACCCAGATCCCATGAAGAACACG-3' 777 HSU69611
Reverse 5'-GCGTTCTTGAAAACACTCCTGGGCCTTACT-3'
ADAM20 Forward 5'-AAAATAGCACACCAGATGGAGTTGCAATTG-3' 702 AF029899
Reverse 5'-ATTCCCACAGTACTTCAGTCTAAATATATT-3'
ADAM21 Forward 5'-TCTGGCTTGGGGTATTTTTG-3' 500 AF158644
Reverse 5'-TTGGCGTGCTACTTCCTTCT-3'
ADAM28 Forward 5'-GCTGTGATGCTAAGACATGT-3' 871 AF137334
Reverse 5'-TGAACAGCCTTTACCATCTG-3'
ADAM30 Forward 5'-AACCAGGTGCCAACTGTAGC-3' 496 AF171932
Reverse 5'-CCCATGGGTTTCATGGATAG-3'
VEGFR-1 Forward 5'-GATGTTGAGGAAGAGGAGGATT-3' 1146 NM002019
Reverse 5'-AAGCTAGTTTCCTGGGGGTATA-3'
VEGFR-2 Forward 5'-GATGTGGTTCTGAGTCCGTCT-3' 562 NM002253
Reverse 5'-CATGGCTCTGCTTCTCCTTTG-3'
Neuropilin-1 Forward 5'-CAACGATAAATGTGGCGATACT-3' 824 NM003873
Reverse 5'-TATACTGGGAAGAAGCTGTGAT-3'
CD31 Forward 5'-CAACGAGAAAATGTCAGA-3' 259 NM000442
Reverse 5'-GGAGCCTTCCGTTCTAGAGT-3'
vWF Forward 5'-GTTCGTCCTGGAAGGATCGG-3' 697 NM000552
Reverse 5'-CACTGACACCTGAGTGAGAC-3'
β -Actin Forward 5'-TGACGGGGTCACCCACACTGTGCCCATCTA-3' 661 NM001101
Reverse 5'-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3'
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scription from the cDNA encoding ADAM15, nucleotides
1091 to 1331 (241 bp), using the DIG RNA labeling kit
(Roche Diagnostics GmbH, Mannheim, Germany). BLASTN
searches were performed to confirm the specificity of the
probes. Hybridization with the probes was performed at 42°C
for 16 h, and the sections were washed in 2× standard saline
citrate/50% formamide, followed by digestion with 10 µg/ml
ribonuclease A (Wako Pure Chemical Industries, Osaka,
Japan). After washing once in 2× standard saline citrate and
twice in 0.2× standard saline citrate and blocking nonspecific
binding with blocking solution (DakoCytomation Norden A/S,
Glostrup, Denmark), they were incubated with mouse anti-dig-
oxigenin antibody (1/750 dilution; Roche Diagnostics GmbH),
and subjected to the following steps using the Catalyzed Sig-
nal Amplification System (DakoCytomation Norden A/S)
according to the manufacturer's protocol. Counterstaining
was performed with hematoxylin.
Characterization of monoclonal antibody against human 
ADAM15 and immunoblotting
A monoclonal antibody against human ADAM15 was devel-
oped using the synthetic peptide corresponding to the amino
acid sequence of the cysteine-rich domain (residues 596 to
612, RDLLWETIDVNGTELNC) of human ADAM15 as an anti-
gen according to our methods [24]. Clones were screened by
enzyme-linked immunosorbent assay using the peptide, and a
clone 240-2C7 was selected as a candidate. The specific
reactivity of the antibody was further evaluated by immunoblot-
ting. The cysteine-rich domain of ADAM15 with FLAG-tag was
expressed in Escherichia coli DH5α  (Takara Bio Inc.) by trans-
fecting with the expression vector pFLAG-ADAM15, which
was prepared by inserting a cDNA fragment encoding the
human ADAM15 cysteine-rich domain (nucleotides 1887 to
1937) [25] into pFLAG-CTC vector (Sigma-Aldrich Inc.). As a
negative control, the vector pFLAG-CTC alone was trans-
fected to DH5α  (mock transfectants). Cell lysates were sub-
jected to SDS-PAGE (15% total acrylamide) under reducing
conditions. The resolved proteins were then transferred to pol-
yvinylidene difluoride membranes (ATTO, Tokyo, Japan),
which were reacted with anti-FLAG antibody (1 µg/ml; Sigma-
Aldrich, Inc.), anti-ADAM15 antibody (1 µg/ml; 240-2C7) or
non-immune mouse immunoglobulin G (IgG) (1 µg/ml; Dako-
Cytomation Norden A/S) after blocking with 5% skim milk.
They were then incubated with horseradish peroxidase-
labeled anti-mouse IgG (1/5000 dilution; Amersham Bio-
sciences Corp., Piscataway, NJ, USA). Immunoreactive bands
were detected with ECL Western blotting reagents (Amer-
sham Biosciences Corp.). As shown in Fig. 1, two protein
bands of 15 kDa and 10 kDa were detected with anti-FLAG
antibody in the cell lysates of ADAM15 transfectants (lane 1)
but not mock transfectants (lane 2). On the other hand, anti-
ADAM15 antibody (240-2C7) selectively reacted with the
band of 15 kDa in the ADAM15 transfectants (Fig. 1, lane 3)
but not mock transfectants (lane 4). The molecular weight of
the immunoreactive 15-kDa band corresponds to that of the
cysteine-rich domain of ADAM15 [25]. Importantly, the immu-
noreactivity of the 15-kDa band was blocked after absorption
of the antibody with the antigen peptide (Fig. 1, lanes 5 and 6).
Blotting with non-immune mouse IgG showed no reactive
bands (data not shown). This indicates that the monoclonal
antibody (240-2C7) is monospecific to the cysteine-rich
domain of ADAM15.
RA synovial tissues (n = 5) were homogenized on ice in a lysis
buffer (50 mM Tris-HCl buffer, pH 7.5, 150 mM NaCl, 10 mM
CaCl2 and 0.05% Brij35) containing a cocktail of proteinase
inhibitors (Roche Diagnostics, GmbH). Supernatants of the
homogenates were subjected to SDS-PAGE (10% total acry-
lamide) under reducing conditions, transferred onto polyvinyli-
dene difluoride membranes and reacted with anti-ADAM15
antibody (240-2C7; 1 µg/ml) or non-immune mouse IgG (1
µg/ml) after blocking with 5% skim milk. They were then incu-
bated with horseradish peroxidase-labeled anti-mouse IgG
and immunoreactive bands were detected with ECL Western
blotting reagents as described above.
Figure 1
Characterization of monoclonal antibody against human ADAM15 Characterization of monoclonal antibody against human ADAM15. 
Lysates of Escherichia coli transfected with the expression vector 
FLAG-ADAM15 containing a cDNA fragment encoding the cysteine-
rich domain of human ADAM15 (lanes 1, 3, 5 and 6) or the pFLAG-
CTC vector alone (lanes 2 and 4) were immunoblotted with anti-FLAG 
antibody (lanes 1 and 2) or anti-ADAM15 antibody (240-2C7) (lanes 3-
6) as described in Materials and methods. The absorption study was 
carried out by incubation of the antibody with 1000-fold excess 
amounts of the peptide for 16 h at 4°C (lane 6). The arrow indicates the 
protein band of the cysteine-rich domain reactive with anti-ADAM15 
antibody. Note that no staining is present with mock transfectants 
(lanes 2 and 4), and that the immunoreactive band with anti-ADAM15 
antibody (lane 5) completely disappears after reaction with the antibody 
absorbed with the peptide (lane 6).Available online http://arthritis-research.com/content/7/6/R1158
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Immunohistochemistry
Paraffin sections of the RA synovial samples were treated with
0.3% H2O2 and 10% normal goat serum to block endogenous
peroxidase and non-specific binding, respectively. As antigen
retrieval, the sections were subjected to microwave treatment
at 500 W for 10 minutes in 10 mM citrate buffer, pH 6.0. They
were then treated with mouse anti-ADAM15 antibody (240-
2C7; 20 µg/ml), rabbit anti-VEGFR-2 antibody (Flk-1; 5 µg/ml;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-
von Willebrand factor (vWF; 15 µg/ml; DakoCytomation Nor-
den A/S) or mouse anti-CD31 antibody (8 mg/ml; DakoCyto-
mation Norden A/S). After the reaction with goat anti-mouse
IgG or goat anti-rabbit IgG conjugated to peroxidase-labeled
dextran polymer (no dilution; En Vison+ Mouse or En Vison+
Rabbit; DakoCytomation Norden A/S), the color was devel-
oped with 3,3'-diaminobenzidine tetrahydrochloride in 50 mM
Tris-HCl buffer, pH 7.6, containing 0.006% H2O2. Counter-
staining was performed with hematoxylin. As for a control, sec-
tions were reacted by replacing the first antibodies with non-
immune mouse IgG or rabbit IgG.
Vascular density
Vascular density in RA and OA synovial tissues was evaluated
by the morphometric analysis of RA and OA tissue sections
immunostained with anti-CD31 antibody without any clinical
information on each sample. Four fields were selected at ran-
dom and vessels with a distinct lumen were counted to
calculate the number of vessels per square millimeter as we
described previously [14]. The average vascular density (ves-
sels/mm2) from the fields for each patient was processed for
further statistical analysis.
Cell cultures of rheumatoid arthritis synovial fibroblasts 
and endothelial cells
RA synovial fibroblasts (SFs) were prepared from RA synovial
tissues obtained at total knee arthroplasty. The tissues were
minced and incubated with 0.04% bacterial collagenase type
I (Worthington Biochemical Corp., Freehold, NJ, USA). Iso-
lated cells were seeded in culture dishes and maintained in
DMEM (Life Technologies) supplemented with 10% fetal
bovine serum (Life Technologies) at 37°C in humidified 5%
CO2 in air. After the cells were cultured in confluence, they
were trypsinized and reseeded in culture dishes. RA SFs at 5–
9 passages were used for experiments. Human umbilical vein
endothelial cells (HUVECs 7943; Cambrex Co., East Ruther-
ford, NJ, USA) were grown in medium EBM-2 supplemented
with EGM-2 (Cambrex Co.).
In order to examine the expression of VEGFR-2 and ADAM15
and exclude the possibility of contamination of cultured RA SF
by endothelial cells, RA SFs at 5–9 passages were seeded on
Lab-Tek II chamber slides (Nalge-Nunc International, Naper-
ville, IL, USA) and subjected to immunohistochemistry for
VEGFR-2, ADAM15, CD31 and vWF as described above. For
a positive control, HUVECs were immunostained with these
antibodies. In addition, mRNA expression of CD31 and vWF
in cultured RA SFs was examined by RT-PCR using the PCR
primers (Table 1).
Stimulation of RA synovial fibroblasts with 
proinflammatory cytokines and/or growth factors
RA SFs were plated on a 60 mm dish at a density of 3 × 105
cells/dish in DMEM supplemented with 10% fetal bovine
serum. The culture media were replaced with serum-free
DMEM containing 0.2% lactalbumin hydrolysate and starved
for 24 h before they were used in experiments. The cells were
treated with tumor necrosis factor-α  (TNF-α ; Dainippon Phar-
matheutical, Osaka, Japan), IL-1α  (Dainippon Pharmatheuti-
cal), transforming growth factor-β  (TGF-β ; R&D Systems,
Minneapolis, MN, USA; 0, 0.1, 1 or 10 ng/ml) or recombinant
VEGF165 (R&D Systems; 0, 1, 10 or 50 ng/ml) for 24 h. For co-
stimulation of RA SFs with TNF-α  and VEGF165, the cells were
first starved with serum-free DMEM containing 0.2%
lactalbumin hydrolysate for 24 h, treated with TNF-α  (1 or 10
ng/ml) for 24 h, and then stimulated with VEGF165 (40 ng/ml)
for 24 h. HUVECs were also stimulated with these cytokines
or growth factors for 24 h after being starved with serum-free
medium EBM-2 containing 1% bovine serum albumin for 24 h.
To block the signaling of VEGF165, RA SFs that had been stim-
ulated with TNF-α  (10 ng/ml) for 24 h were incubated with
SU1498 (1 or 10 µM; Calbiochem, San Diego, CA, USA), a
selective VEGFR-2 tyrosine kinase inhibitor [26,27], for 30
minutes and then treated with VEGF165 (40 ng/ml) for 24 h.
HUVECs were also treated with SU1498 in a similar way
except for no treatment with TNF-α . To exclude the possible
involvement of VEGFR-1 in ADAM15 expression, RA SFs and
HUVECs were stimulated with recombinant human placenta
growth factor (PlGF; 1, 10 or 50 ng/ml; R&D Systems), which
selectively binds to VEGFR-1 [28].
Statistics
Comparisons between two independent groups were deter-
mined by Mann-Whitney U test. Spearman's rank correlation
was used for analysis of the relationship between relative
ADAM15 mRNA expression and vascular density. P-values
less than 0.05 were considered significant.
Results
Screening of mRNA expression of ADAMs and relative 
expression levels of ADAM15 in RA and OA synovial 
tissues
The mRNA expression of 10 different ADAMs (8, 9, 10, 12,
15, 17, 20, 21, 28 and 30) with a putative metalloproteinase
motif was screened by RT-PCR analysis in eight RA and eight
OA synovial samples. ADAM9, ADAM10 and ADAM17 were
expressed in more than 88% of RA samples, but their expres-
sion was also observed in more than 75% of OA samples (Fig.
2). ADAM12 was expressed in 38% and 13% of RA and OA
samples, respectively. ADAMs 8, 20, 21, 28 and 30 wereArthritis Research & Therapy    Vol 7 No 6    Komiya et al.
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expressed in less than 13% of both RA and OA samples. On
the other hand, ADAM15 was intensely expressed in all the RA
synovial samples, whereas it was detected in 63% of OA sam-
ples (Fig. 2). Because of the more selective expression of
ADAM15 in RA than in OA, we focused on ADAM15 for fur-
ther studies. When the expression was examined in a larger
number of RA and OA samples, ADAM15 was detected in
100% of the RA samples (16 of 16 cases) and in 60% of the
OA samples (12 of 20 cases) (data not shown). By real-time
quantitative PCR analysis, the expression levels (ratio of
ADAM15 to ribosomal 18S RNA) were significantly higher in
RA samples (0.344 ± 0.276; n = 10) than in OA samples
(0.091 ± 0.030; n = 10) (p < 0.01; Fig. 3).
Figure 2
mRNA expression of ADAM species in rheumatoid arthritis (RA) and osteoarthritis (OA) synovial samples mRNA expression of ADAM species in rheumatoid arthritis (RA) and osteoarthritis (OA) synovial samples. Total RNA was extracted from eight RA 
(lanes 1-8) or eight OA (lanes 9-16) synovial samples, and reverse-transcribed into cDNA, followed by PCR as described in Materials and methods. 
C, positive controls.Available online http://arthritis-research.com/content/7/6/R1158
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Expression of ADAM15 in RA synovial tissues studied by 
in situ hybridization, immunohistochemistry and 
immunoblotting
Cells expressing ADAM15 mRNA were examined by in situ
hybridization. Synovial lining cells, endothelial cells of blood
vessels and macrophage-like cells in the sublining layer were
labeled with the anti-sense RNA probe (Fig. 4a), whereas the
sense probe gave only a background signal in these cells (Fig.
4b). Immunohistochemical studies showed that ADAM15 was
localized to synovial lining cells, endothelial cells of blood ves-
sels and macrophage-like cells in the sublining layer of the RA
synovium (Fig. 5a,b), confirming the findings from in situ
hybridization. No staining was obtained with non-immune IgG
(Fig. 5f). VEGFR-2 was immunolocalized to some synovial lin-
ing cells and endothelial cells of blood vessels in RA samples
(Fig. 5c), but vWF and CD31 were almost exclusively localized
to endothelial cells (Fig. 5d,e).
When homogenates of RA synovial tissues were subjected to
immunoblotting analysis, eight major immunoreactive bands of
100, 76, 66, 47, 41, 38, 34 and 29 kDa were observed (Fig.
6, lane 2). Because the molecular weight of the 100-kDa band
is similar to that of the precursor form of ADAM15 [12,25], this
band appears to correspond to proADAM15. On the other
hand, at least some of the other bands are considered to be
active ADAM15 forms containing the metalloproteinase
domain because of their positive immunoreactivity to the anti-
body specific to the cysteine-rich domain and their molecular
weights. An immunoreactive band of 58 kDa was a non-spe-
cific reaction, because it was also detected with non-immune
mouse IgG (Fig. 6, lane 1).
Correlation between ADAM15 expression and vascular 
density in RA and OA synovial tissues
No definite correlation between relative mRNA expression lev-
els of ADAM15 and the separate or total histological scores of
RA and OA synovial tissues was observed (data not shown).
Thus, we further evaluated vascular density in the RA and OA
synovial tissues, by counting CD31-positive vessels in synovial
tissue sections, and compared it with the mRNA expression
levels of ADAM15. A linear correlation was found between
expression levels and vascular density in RA and OA synovial
tissues (r = 0.907, p < 0.001; n = 20; Fig. 7).
Effect of cytokines and growth factors on ADAM15 
expression in RA SFs and HUVECs
When the expression of ADAM15 in RA SFs was examined by
RT-PCR, it was constitutively expressed regardless of the pas-
sage numbers (5 to 9) of the cells (Fig. 8a). Expression was
decreased to low levels in a time-dependent manner, however,
after starvation with serum-free medium for up to 72 h (Fig.
8b). To test the effect of cytokines and growth factors on
ADAM15 expression, RA SFs were stimulated with TNF-α , IL-
1α , TGF-β  or VEGF165; however, no changes in mRNA
expression were found with these factors (Fig. 8c,d). In
contrast, VEGF165 appeared to selectively enhance ADAM15
expression in HUVECs (Fig. 8d), whereas TNF-α , IL-1α  or
TGF-β  did not alter the expression (data not shown). Using
real-time quantitative PCR, we found that the relative expres-
sion levels of ADAM15 mRNA (ratio of ADAM15 to ribosomal
18S) in HUVECs are significantly 2.2-fold higher after treat-
ment with VEGF165 (p < 0.05).
Regulation of VEGFR-1, VEGFR-2 and neuropilin-1 
expression by cytokines and growth factors in RA SFs 
and HUVECs
As previously reported [15,29], HUVECs expressed the three
major VEGF receptors (VEGFR-1, VEGFR-2 and neuropilin-
1), but RA SFs expressed only neuropilin-1 under unstimu-
lated conditions (Fig. 9a). Because the data that VEGF165
stimulated ADAM15 expression only in HUVECs suggested
that the effect is dependent on the expression of VEGF recep-
tors, we tried to induce VEGF receptors by treating RA SFs
with cytokines and growth factor and found that TNF-α , but
not IL-1α  or TGF-β , can induce VEGFR-2 expression without
affecting the expression of VEGFR-1 or neuropilin-1 (Fig. 9b).
Figure 3
The mRNA expression levels of ADAM15 in rheumatoid arthritis (RA) or  osteoarthritis (OA) synovial samples The mRNA expression levels of ADAM15 in rheumatoid arthritis (RA) or 
osteoarthritis (OA) synovial samples. The relative expression levels 
(ADAM15:ribosomal 18S ratios) were determined by real-time PCR 
analysis as described in Materials and methods. Bars indicate the mean 
values of the 10 samples of RA and OA synovial tissues. Asterisk indi-
cates p < 0.01.Arthritis Research & Therapy    Vol 7 No 6    Komiya et al.
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Stimulation of ADAM15 expression by VEGF165 in 
VEGFR-2-expressing RA SFs
As TNF-α  induced VEGFR-2 expression in RA SFs, we further
examined whether VEGF165 enhances ADAM15 expression in
VEGFR-2-expressing RA SFs. After stimulation of RA SFs with
TNF-α  or VEGF165 alone, ADAM15 mRNA expression, which
was only weak after starvation of the cells, did not change (Fig.
10a). When the cells were sequentially treated with TNF-α  and
VEGF165, however, the level of ADAM15 expression appeared
to be increased (Fig. 10a). Real-time quantitative PCR analysis
demonstrated that the expression levels are significantly 2.2-
fold higher in RA SFs treated with TNF-α  and VEGF165 com-
pared with the control without treatment (p < 0.05).
VEGFR-2 signaling in VEGF165-stimulated ADAM15 
expression in RA SFs
To examine the involvement of VEGFR-2 signaling in the stim-
ulation of ADAM15 expression with TNF-α  and VEGF165, RA
SFs were incubated with SU1498, a selective VEGFR-2 tyro-
sine kinase inhibitor, prior to the stimulation with VEGF165 and
ADAM15 mRNA expression was examined. ADAM15
expression decreased with 1 µM SU1498 and was completely
suppressed with 10 µM SU1498, while VEGFR-2 expression
was not affected by the treatment with such concentrations of
the inhibitor (Fig. 10b). The enhanced expression of ADAM15
in HUVECs was also inhibited by the treatment with SU1498
(data not shown). PlGF, which selectively binds to VEGFR-1,
did not affect the mRNA expression of ADAM15 in either RA
SFs or HUVECs (data not shown).
Immunohistochemical demonstration of ADAM15 
expression and VEGFR-2 induction by TNF-α  in RA SFs
Protein expression of ADAM15 and endothelial cell markers in
cultured RA SFs was examined by immunohistochemistry.
ADAM15 was immunolocalized to RA SFs and HUVECs (Fig.
11a,e), whereas no staining was observed with non-immune
IgG (Fig. 11d,h). On the other hand, although VEGFR-2, vWF
and CD31 were all immunostained in HUVECs (VEGFR-2 and
vWF, Fig. 11f,g; CD31, data not shown), RA SFs were nega-
tive for these endothelial cell markers (vWF, Fig. 11c; VEGFR-
2 and CD31, data not shown). When RA SFs were treated
with TNF-α  for 24 h, however, they were positively immunos-
tained with anti-VEGFR-2 antibody (Fig. 11b). In accordance
with the immunohistochemical data, the mRNA expression of
CD31 and vWF in untreated RA SFs was not detected by RT-
PCR (data not shown).
Discussion
In the present study, we have demonstrated that among the 10
different ADAM species with the putative metalloproteinase
motif, ADAM15 is more frequently and intensely expressed in
RA synovium than in OA synovium. The mRNA expression
patterns of the ADAM species in synovial tissues could be
classified into three groups: constitutive expression in both RA
and OA samples (ADAM9, ADAM10 and ADAM17); negligi-
Figure 4
In situ hybridization of ADAM15 in rheumatoid arthritis synovial tissues In situ hybridization of ADAM15 in rheumatoid arthritis synovial tissues. Paraffin sections were reacted with digoxigenin-labeled anti-sense or sense 
RNA probes as described in Materials and methods. Note (a) a positive signal in the synovial lining cells (arrows), endothelial cells (black arrow-
head) and macrophage-like cells (white arrowhead) with anti-sense probe, whereas (b) there was only a background signal with the sense probe. 
Scale bar, 50 µm.Available online http://arthritis-research.com/content/7/6/R1158
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Figure 5
Immunolocalization of ADAM15, VEGFR-2, vWF and CD31 in rheumatoid arthritis (RA) synovial tissues Immunolocalization of ADAM15, VEGFR-2, vWF and CD31 in rheumatoid arthritis (RA) synovial tissues. Paraffin sections were stained with (a) 
hematoxylin and eosin or immunostained with antibodies against (b) ADAM15, (c) VEGFR-2, (d) vWF or (e) CD31, or (f) non-immune mouse IgG 
as described in Materials and methods. (b) Note that ADAM15 is expressed in synovial lining cells and endothelial cells of blood vessels in the sub-
lining layer. Immunostained sections were counterstained with hematoxylin. Arrows, synovial lining cells; arrowheads, endothelial cells of blood ves-
sel. Scale bar, 100 µm.Arthritis Research & Therapy    Vol 7 No 6    Komiya et al.
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ble or no expression in RA or OA (ADAM8, ADAM20,
ADAM21, ADAM28 and ADAM30); and more selective
expression in RA than in OA (ADAM12 and ADAM15). When
the expression patterns were compared with those in human
astrocytic tumor and normal brain tissues [9], they were
different in that more ADAM species, including ADAM9,
ADAM10, ADAM15, ADAM17, ADAM20, ADAM21 and
ADAM28, are constitutively expressed in brain tumor and nor-
mal brain tissues, but similar in that the expression of ADAM8
and ADAM30 is negligible. ADAM12 was selectively overex-
pressed in the highly malignant glioblastomas and appeared to
play a key role in the tumor cell proliferation through shedding
of heparin-binding epidermal growth factor [9]. This was not
the case in RA synovium, however, because ADAM12 expres-
sion was confined to less than 40% of the RA samples and the
expression level did not correlate with synovial lining cell
hyperplasia.
A study by Bohm and co-workers [12] described the expres-
sion of ADAM15 in RA and OA synovial tissues by immunohis-
tochemistry and in situ hybridization, but their study did not
quantitatively analyze the expression levels. The present study
has provided the first evidence that the mRNA expression level
of ADAM15 is significantly 3.8-fold higher in RA than in OA.
Our data of in situ hybridization and immunohistochemistry in
RA synovium demonstrated that synovial lining cells, endothe-
lial cells of blood vessels and macrophage-like cells in the sub-
lining layer are responsible for the expression of ADAM15. The
finding confirms the previous observation that synovial lining
cells and macrophage-like cells express ADAM15 [12], but
further indicate that endothelial cells, which are positive for
CD31 and vWF, express ADAM15 in RA synovium. The
expression by RA synovial lining cells and endothelial cells
was also supported by our immunohistochemical data with
cultured RA SFs and HUVECs. Interestingly, several ADAM15
species with molecular weights ranging from 100 kDa to 29
kDa were immunoblotted with RA synovial tissues. The data
suggest that proADAM15 is susceptible to proteolytic cleav-
ages and processed into fragments including active forms in
RA synovial tissues.
Figure 6
Immunoblotting of ADAM15 in rheumatoid arthritis (RA) synovial tissues Immunoblotting of ADAM15 in rheumatoid arthritis (RA) synovial tis-
sues. Homogenates of RA synovial tissues were prepared and sub-
jected to immunoblotting with anti-ADAM15 antibody specific to the 
cysteine-rich domain of ADAM15 (240-2C7) (lane 2) or non-immune 
mouse IgG (lane 1) as described in Materials and methods. Immunore-
active bands of 100, 76, 66, 47, 41, 38, 34 and 29 kDa are indicated 
(arrow heads). The 58 kDa protein band is considered to be a non-spe-
cific band because it is also detected with non-immune IgG (lanes 1 
and 2).
Figure 7
Correlation between ADAM15 mRNA expression levels and vascular  density in synovial tissues Correlation between ADAM15 mRNA expression levels and vascular 
density in synovial tissues. Vascular density was determined by the 
morphometric analysis of the CD31-immunostained sections and corre-
lation was examined by Spearman's rank correlation. Note a direct cor-
relation between the parameters (r = 0.907, p < 0.001; n = 20). Open 
and closed circles indicate osteoarthritis (OA) and rheumatoid arthritis 
(RA) synovial samples, respectively.Available online http://arthritis-research.com/content/7/6/R1158
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One of the important findings in the present study is that
VEGF165 up-regulates the expression of ADAM15. Overex-
pression of ADAM species is known in tumor cell lines, for
example, ADAM10, ADAM12 and ADAM15 in hematological
malignant tumor cell lines [30], and ADAM9, ADAM10,
ADAM15 and ADAM17 in prostate cancer cell lines [31].
Although dihydrotestosterone modulates the gene expression
of ADAM9, ADAM10 and ADAM17 in an androgen-depend-
ent cell line [32], the expression of the ADAM species in these
tumor cell lines may result mainly from the gene regulation
associated with transformation of the cells. Phorbol 12-myr-
istate 13-acetate stimulates human monocyte-like cell line
THP-1 to enhance expression of ADAM8, ADAM9 and
ADAM17, but decreases ADAM15 expression [33]. In addi-
tion, platelet-derived growth factor stimulates human vascular
smooth muscle cells to overexpress ADAM9 and ADAM15
[34]. In human OA chondrocytes, IL-1 and/or retinoic acid up-
regulate ADAM15 and ADAM17, but down-regulate ADAM9
[35]. In the present study, however, we have shown that
VEGF165, but not IL-1α , TNF-α  or TGF-β , stimulates HUVECs
Figure 8
Effects of passages, starvation, cytokines and growth factors on ADAM15 expression in cultured cells Effects of passages, starvation, cytokines and growth factors on ADAM15 expression in cultured cells. The mRNA expression of ADAM15 was 
examined by RT-PCR at 25 cycles as described in Materials and methods. (a) Effect of passages on the mRNA expression of ADAM15 in rheuma-
toid arthritis (RA) synovial fibroblasts (SFs). Lanes 1 to 5 indicate passages 5, 6, 7, 8 and 9 of RA SFs. (b) Effect of starvation on the mRNA expres-
sion of ADAM15 in RA SFs. (c) Effect of tumor necrosis factor (TNF)-α  (0, 0.1, 1 and 10 ng/ml), IL-1α  (0, 0.1, 1 and 10 ng/ml) or transforming 
growth factor (TGF)-β  (0, 0.1, 1 and 10 ng/ml) on the mRNA expression of ADAM15 in RA SFs after stimulation with these factors for 24 h. (d) Reg-
ulation of the mRNA expression of ADAM15 by vascular endothelial growth factor (VEGF)165 in RA SFs and human umbilical vein endothelial cells 
(HUVECs). Cells were stimulated with VEGF165 (0, 1, 10 and 50 ng/ml) for 24 h. Note that VEGF165 enhances the expression of ADAM15 only in 
HUVECs.Arthritis Research & Therapy    Vol 7 No 6    Komiya et al.
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to enhance the gene expression of ADAM15. In addition, our
data indicate that TNF-α  induces VEGFR-2 expression in RA
SFs, and VEGF165 up-regulates ADAM15 expression in the
TNF-α -stimulated RA SFs. The specific involvement of
VEGFR-2 signaling in the enhanced ADAM15 gene
expression was demonstrated by the findings that the stimula-
tion was blocked with SU1498, an inhibitor of VEGFR-2, and
that PlGF, which selectively binds to VEGFR-1, had no effect
on ADAM15 expression. Thus, these results demonstrate for
the first time that VEGF165 is a stimulator of ADAM15 gene
expression in cells that express VEGFR-2. Although VEGFR-2
expression was originally thought to be specific to endothelial
cells, accumulated evidence indicates that many cell types,
such as hematopoietic stem cells [36], megakaryocytes [36],
retinal progenitor cells [37] and OA chondrocytes [19],
express the receptor. Because RA synovial fluids contain high
amounts of TNF-α  and VEGF165 [38,39], it is reasonable to
think that synovial lining cells are co-stimulated with these fac-
tors to induce VEGFR-2 and ADAM15 in RA synovial tissue.
In fact, VEGFR-2 and ADAM15 were immunolocalized to RA
synovial lining cells in the present study, suggesting the valid-
ity of the hypothesis.
The present study has demonstrated that the expression levels
of ADAM15 directly correlate with the vascular density of syn-
ovial tissues. This suggests the possible involvement of
ADAM15 in the angiogenic steps of RA synovial tissues,
which include sprouting, migration and proliferation of
endothelial cells, and maturation of vessels [40]. The notion
that ADAM15 may be implicated in pathological angiogenesis
is supported by recent experimental data: ADAM15 is up-reg-
ulated on the angiogenic endothelial cell surface [41];
ADAM15 has proteinase activity to digest gelatin and type IV
collagen [42], which is essential for endothelial cells to sprout
and migrate; ADAM15 interacts with α vβ 3 and α 5β 1 integrins
[43], which promote cell migration and proliferation of
Figure 9
Effects of cytokines and growth factors on expression of vascular endothelial growth factor receptors (VEGFRs) Effects of cytokines and growth factors on expression of vascular endothelial growth factor receptors (VEGFRs). The mRNA expression of the VEG-
FRs was examined by RT-PCR at 30 cycles as described in Materials and methods. (a) The expression of VEGFR-1, VEGFR-2 and neuropilin-1 in 
rheumatoid arthritis (RA) synovial fibroblasts (SFs) of different passages and human umbilical vein endothelial cells (HUVECs). Lanes 1 to 5 corre-
spond to RA SFs of passages 5, 6, 7, 8 and 9, respectively. (b) The mRNA expression of VEGFR-1, VEGFR-2 and neuropilin-1 in RA SFs after 24 h 
stimulation with tumor necrosis factor (TNF)-α  (0, 0.1, 1, 10 and 50 ng/ml), IL-1α  (0, 0.1, 1, 10 and 50 ng/ml) or transforming growth factor (TGF)-β  
(0, 0.01, 0.1, 1 and 10 ng/ml). Note that TNF-α  selectively induces the mRNA expression of VEGFR-2 in RA SFs.Available online http://arthritis-research.com/content/7/6/R1158
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endothelial cells and smooth muscle cells [44,45]; inhibition of
ADAM15's functions by antibodies, antisense oligonucleotide
and metalloproteinase inhibitor decreases cell migration [42];
ADAM15-deficient mice show reduced neovascularization in
hypoxia-induced proliferative retinopathy compared to wild-
type control mice [8]; and the recombinant human disintegrin
domain of ADAM15 itself exhibits anti-angiogenic activity,
probably by disturbing the interaction between ADAM15 and
integrins, leading to inhibition of endothelial cell migration and
proliferation [46]. In addition, Ham et al. [47] have reported
that ADAM15 is co-localized with vascular endothelial
cadherin in the adherens junctions of endothelial cells and this
cadherin drives ADAM15 to the cell junctions. Moreover,
overexpression of ADAM15 is known to enhance cell-cell
interactions [48]. VEGF is highly expressed in RA synovial tis-
sues and believed to play a central role in synovial
angiogenesis [49], and it stimulates ADAM15 expression in
endothelial cells as shown in the present study. Altogether,
these data suggest the possibility that ADAM15 may play a
role in maturation of the blood vessels newly formed by VEGF-
induced angiogenesis through enhancing endothelial cell-cell
interaction in the RA synovium.
The biological significance of the overexpression of ADAM15
in RA synovial lining cells and macrophage-like cells is not
clear at present. The fact that RA synovial lining cells express
α 5β 1 and α vβ 3 integrins [50-52], however, suggests the
possibility that ADAM15 may function as a binding molecule
to reinforce cell-cell and/or cell-ECM interactions. On the
other hand, because ADAM15 is reported to have proteolytic
activities towards ECM components (gelatin and type IV colla-
gen) [42], it is possible that ADAM15 may be involved in the
degradation of cartilage ECM at the synovial cartilage junction.
In addition, ADAM15 is known to produce soluble forms of
CD23 through ectodomain shedding of membrane-bound
CD23 on cell membranes of inflammatory cells [53]. Soluble
forms of CD23, which are elevated in synovial fluid and sera of
RA patients [54-56], promote the production of inflammatory
cytokines by macrophages [57] and stimulate monocytes and
T cells [58]. Thus, these data suggest that ADAM15 may play
a role in the aggravation of inflammation of RA synovitis
through production of soluble forms of CD23, which trigger
inflammatory process via monokine release and stimulate
monocytes and T cells [59,60]. In contrast to the prospective
role of ADAM15 in joint destruction, a recent study has dem-
onstrated that aging mice with a targeted disruption of
ADAM15 exhibit accelerated development of OA changes in
Figure 10
Effects of tumor necrosis factor-α , vascular endothelial growth factor165 and SU1498 on ADAM15 expression Effects of tumor necrosis factor-α , vascular endothelial growth factor165 and SU1498 on ADAM15 expression. (a) Effect of tumor necrosis factor 
(TNF)-α  and vascular endothelial growth factor (VEGF)165 on ADAM15 expression. After starvation, rheumatoid arthritis (RA) synovial fibroblasts 
(SFs) were treated with 10 ng/ml TNF-α  and/or 40 ng/ml VEGF165 for 24 h, and then the expression of ADAM15, vascular endothelial growth factor 
receptor (VEGFR)-1, VEGFR-2 and neuropilin-1 was examined by RT-PCR at 25 cycles (ADAM15 and β -actin) or 30 cycles (VEGFR-1, VEGFR-2 
and neuropilin-1) as described in Materials and methods. Note that treatment with TNF-α  induces VEGFR-2 and co-treatment with TNF-α  and 
VEGF165 stimulates the mRNA expression of ADAM15 in RA SFs. (b) Effect of SU1498 on ADAM15 expression. After starvation for 24 h, RA SFs 
were stimulated with 10 ng/ml TNF-α  for 24 h to induce VEGFR-2. Then, the cells were treated with SU1498 (0, 1 and 10 µM) for 30 minutes and 
stimulated with 40 ng/ml VEGF165 for 24 h. The mRNA expression of ADAM15 was determined by RT-PCR at 25 cycles as described in Materials 
and methods. Note that the stimulated expression of ADAM15 mRNA is inhibited by the treatment with SU1498, while the expression of VEGFR-2 
mRNA is not affected by the treatment.Arthritis Research & Therapy    Vol 7 No 6    Komiya et al.
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the articular cartilage, and suggested that ADAM15
expressed by chondrocytes has a homeostatic, rather than a
destructive, role in the cartilage [61]. Thus, further studies are
definitely needed to elucidate the exact role of this unique and
multifunctional molecule in RA and OA.
Conclusion
Our results demonstrate that ADAM15 is overexpressed in lin-
ing cells, endothelial cells of blood vessels and macrophage-
like cells in the sublining layer of RA synovium, with a direct
correlation with vascular density in the synovium, and that the
expression of ADAM15 in RA SFs is up-regulated by the
action of VEGF165 via VEGFR-2. These data suggest that
ADAM15 is involved in angiogenesis in the RA synovium.
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